About
AboutNovo GroupLeadershipResponsibilityNovo Nordisk Foundation
Investments
InvestmentsAreas
Life Science
Seed InvestmentsVenture InvestmentsGrowth InvestmentsPrincipal InvestmentsBioindustrial Investments
Capital Investments
StrategyRegions
North AmericaEuropeAsia
Portfolio
People & Careers
PeopleCareers
Open positions
News & Reports
News & ReportsFacts & figuresPress FAQMedia library
Natalie Sacks

Department

Venture Investments

Position

Venture Partner

Dr. Natalie Sacks joined Venture Investments in 2022 as a Venture Partner based in the San Francisco office.

Dr. Sacks is an oncologist and drug developer with over 20 years of experience in the biotechnology industry.  Prior to joining Venture Investments, she served as the Chief Medical Officer at Harpoon Therapeutics. Prior to that, she held various development and executive leadership roles at multiple companies including at Onyx Pharmaceuticals (acquired by Amgen), Aduro, Exelixis, and Cell Genesys. She has been responsible for all aspects of development ranging from initial IND to the late-stage development of commercially available oncology therapeutics.

Dr. Sacks held a faculty appointment at the University of California, San Francisco for more than ten years, where she was a volunteer assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her B.A. in Mathematics from Bryn Mawr College, her M.S. in Biostatistics from the Harvard University School of Public Health, and her M.D. from the University of Pennsylvania School of Medicine.

Investing to benefit people and the planet

Novo Holdings A/S

Tuborg Havnevej 19

2900 Hellerup Denmark

+45 3527 6500 CVR# 24257630

Media Relations

Christian Mostrup Scheel

Head of Public Relations

cims@novo.dk +45 3067 4805

Novo Holdings Equity US Inc.*

One Market Plaza, Floor 17 of the Steuart Tower

San Francisco, CA 94105 USA

+1 (415) 363-0858

Novo Holdings Equity Asia Pte. Ltd.*

#40-01, 6 Battery Road

Singapore 049909

Novo Holdings Equity US Inc.*

200 Clarendon Street, Floor 45

Boston, MA 02116 USA

Novo Holdings (UK office)

16 Berkeley Street

London W1J 8DZ

Novo Ventures (US) Inc.*

200 Clarendon Street, Floor 45

Boston, MA 02116 USA

Privacy noticeWhistleblowerArticles of association Policy on data ethicsElectronic invoicingDiversity policy

*Novo Ventures (US) Inc., Novo Holdings Equity US Inc., comprising Novo Growth and Principal Investments, and Novo Holdings Equity Asia Pte. Ltd. are separate legal entities that provide certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.

Follow us